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ABSTRACT 
 
The peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors involved in 
energy homeostasis. Their natural ligands are fatty acids and there are three different PPAR isoforms; PPARA, 
PPARG and PPARD. They are encoded by separate genes and have distinct functions, due to different tissue 
expression and affinity for ligands. PPARA controls genes involved in fatty acid oxidation, PPARG regulates 
genes important for fatty acid storage, and PPARD controls genes implicated in lipid oxidation and lipoprotein 
metabolism. Primates and humans treated with a PPARD agonist (GW501516) resulted in improved insulin 
sensitivity, increased HDL and decreased LDL cholesterol levels, making it a putative drug candidate for 
treatment of metabolic disease. PPARD has recently been assigned a beneficial role in macrophages, by 
inducing a switch from proinflammatory (M1) to antiinflammatory (M2) macrophages. 
     To characterize additional target genes of PPARD involved in the lipoprotein metabolism, the effect of 
PPARD activation on the apolipoprotein A-II (apoA-II) gene was investigated in human hepatoma cells. 
ApoA-II is one of the major proteins in the HDL particles. Treatment with GW501516 increased apoA-II 
promoter activity and mRNA levels in hepatoma cell lines. A site located at -737/-717 in the promoter was 
identified as the functional PPAR response element (PPRE). These results suggest that increased expression of 
the apoA-II gene is one of the reasons for the beneficial effects on lipoprotein metabolism after treatment with 
the PPARD agonist. 
     To investigate whether PPARs could regulate the alanine aminotransferase (ALT) genes, the effect of 
PPARA, G and D agonist treatment was studied. ALT activity in plasma is used as a marker for hepatotoxicity 
in humans. During a clinical trial with the PPARA ligand, AZD4619, the plasma ALT activity increased in 
some patients and in vitro studies showed that ALT1 protein and mRNA expression was induced by treatment 
with PPARA agonists in primary hepatocytes. Similarly, transient transfection of a promoter construct of ALT1 
in HuH-7 cells showed increased activity mediated via a PPRE located at -574 after treatment with PPAR 
agonists. This study shows that the ALT1 gene is regulated by PPARs and that PPAR drugs might contribute to 
increased ALT activity in serum.  
     To explore regulation of the PPARD gene by posttranscriptional events, 5'- and 3'-RACE were performed 
on cDNA obtained from placenta, adipose tissue and pancreas. Both 5'- and 3'-alternative splicing of PPARD 
was identified. Coupled transcription/translation showed that the length and number of upstream AUGs in the 
5'-UTR had a major impact on translational efficiency. Further, the promoter located upstream of exon one was 
verified as the major promoter, using reporter gene assays. A 3'-splice variant encoding a truncated PPARD 
protein, PPARD2, was shown to be a negative regulator of the full length receptor, PPARD1, in transient 
transfection assays.  
     To identify whether PPARD is regulated by microRNA (miRNA), the 3'-UTR was analysed in silico. Two 
putative miRNA target sites were identified in the PPARD 3'-UTR; miR-9 and miR-29. The miR-9 was 
verified as a functional miRNA targeting PPARD. However, PPARD mRNA levels remained unaffected by 
miR-9 expression, indicating that only the translation of PPARD was inhibited. Since both miR-9 and PPARD 
have been shown to play important roles in the inflammatory response of monocytes, the regulation of PPAR 
expression by miR-9 was investigated in these cells. A suppressive role of miR-9 on PPARD expression was 
identified in monocytes after LPS treatment but not in M1 or M2 macrophages, suggesting that the regulatory 
role of miR-9 on PPARD is exerted in monocytes, before differentiating into macrophages. 
     In summary, this thesis describes additional functions and ways of regulation of the ubiquitously expressed 
transcription factor PPARD with a major role in both health and disease. 
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Hjärt- och kärlsjukdomar såsom hjärtinfarkt, hjärtsvikt och stroke (slaganfall) är de vanligaste dödsorsakerna i 
västvärlden. Hjärt- och kärlsjukdomar beror av en fettansamling i kärlen under många decennier som med tiden 
leder till åderförkalkning, så kallad ateroskleros. När åderförkalkningen blockerar kärl drabbas vävnader av 
syrebrist vilket leder till sjukdom. Uppkomst av åderförkalkning beror av flera faktorer, där övervikt, höga 
blodfetter, högt blodtryck och högt blodsocker är de viktigaste. Dessa faktorer påverkas i sin tur av ärftlighet 
men även av våra livsvanor, där rökning, fysisk inaktivitet, samt matvanor spelar en huvudsaklig roll. 
     Peroxisom proliferator-aktiverade receptorer (PPAR) är en grupp proteiner som reglerar gener som håller 
kroppen i jämvikt vid ökat eller minskat energiintag. De fungerar genom att binda till styrregioner i gener med 
betydelse för inlagring eller förbränning av fett. Det finns tre olika medlemmar i PPAR-familjen; PPAR alfa 
(PPARA), PPAR gamma (PPARG) och PPARD delta (PPARD). PPARA finns mest i levern, PPARG i fettväv 
medan PPARD finns i alla kroppens celler. Det har visat sig att aktivering av PPARD med en syntetisk 
molekyl, ”GW501516” ökar mängden av det ”goda” HDL-kolesterolet och minskar det ”onda” LDL-
kolesterolet. Syftet med denna avhandling var att identifiera gener som styrs av PPARD, samt studera hur 
nivåerna av PPARD styrs.  
     I den första studien undersöks resultatet av aktivering av PPARD i leverceller med GW501516 på 
apolipoprotein A-II (apoA-II) -genen. ApoA-II är ett vanligt förekommande protein i HDL-partikeln. Studien 
visar att PPARD kan binda till ett regulatoriskt område i apoA-II-genen och öka dess aktivitet, vilket skulle 
kunna tyda på att det är en av mekanismerna för hur PPARD-aktivering kan öka mängden HDL-kolesterol.  
     I den andra studien undersöks hur en potentiell läkemedelskandidat som binder PPARA, AZD4619, 
påverkar alaninaminotransferas (ALT), ett leverenzym som traditionellt används för att mäta leverskada. I en 
klinisk studie med AZD4619 observerades höjningar i plasmanivåerna av ALT, tydande på leverskada. Vår 
studie visar att aktivering av PPARA men även av PPARG och PPARD, kan styra ALT-genen och på så sätt 
öka mängden ALT-protein i cellerna. Slutsatsen är att ALT-höjningarna i den kliniska studien med AZD4619 
inte nödvändigtvis berodde på leverskada utan kan ha orsakats av en regulatorisk effekt av PPARA. 
     Den tredje studien visar att nivåerna av PPARD kan styras genom alternativ splicing. För att en gen ska 
kunna ge upphov till ett protein krävs ett mellansteg där messenger-RNA (mRNA) bildas. För PPARD kunde 
vi se att det fanns olika typer av mRNA där längre varianter inte gav upphov till protein lika lätt som kortare 
varianter. Vi fann också en kortare PPARD proteinvariant, PPARD2, som kunde hämma funktionen av 
fullängdsvarianten, PPARD1. Slutsatsen är att alternativ splicing reglerar mängden av tillgängligt PPARD 
protein i kroppen, vilket skulle kunna ha betydelse vid exempelvis förändringar beroende på fysiologiska 
omständigheter i olika organ. 
     Den fjärde studien visar att PPARD kan styras genom regulatoriska molekyler som kallas micro-RNA 
(miRNA) som binder till mRNA-molekyler av PPARD och hämmar dem från att bli protein. Studien visade att 
miR-9 men inte miR-29 kunde hämma PPARD. Vid behandling med inflammatoriska substanser, då mängden 
miR-9 ökar, kunde vi se att effekten av PPARD på sina målgener minskade i monocyter, som är vita 
blodkroppar ansvariga för en snabb effekt av immunförsvaret vid en infektion. Vi undersökte även om det var 
skillnad i miR-9-mängd mellan proinflammatoriska M1- och antiinflammatoriska M2 makrofager, men såg 
ingen skillnad mellan dessa subtyper. Slutsatsen är att miR-9 kan ha en effekt på PPARD i monocyter men 
verkar ha mindre betydelse i makrofager. 
     Studierna i denna avhandling har visat att apoA-II- och ALT1-generna styrs av PPARD samt att mängden 
PPARD kan moduleras genom de regulatoriska mekanismerna alternativ splicing och miRNA-inhibering.  
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PREFACE 
 
In this thesis I will introduce the research field of cardiovascular disease and the 
importance of the regulation and activation of the nuclear receptor PPARD. However, 
before doing so I would like to explain my reasons for choosing this particular topic. 
Ever since I was a child I have enjoyed running and jumping, and for many years I 
participated in track and field events. Naturally I became fascinated by physiology and 
the human body, so after graduating from Upper Secondary School, I studied 
“Integrative Human Medicine” for one year at Karolinska Institutet. In this time the 
topic of transcription factors was introduced to me and during a ten-week literature 
study about the AhR nuclear translocator (ARNT), my interest for research and 
transcription factors grew. A few years later, during my Master’s in Biomedicine I was 
introduced to the nuclear receptor PPARD in a lecture given by Associate Professor 
Ewa Ehrenborg. I was fascinated by the concept of a transcription factor that had 
important functions in metabolism but that could also be modulated by exercise. I was 
very happy when Ewa accepted me as a summer student in her group and after 
finishing my Master’s thesis on PPARD I was offered a PhD position and could not 
resist the opportunity.  
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1 INTRODUCTION 
 
1.1 CARDIOVASCULAR DISEASE 
Cardiovascular diseases (CVD) include a group of disorders of the heart and blood 
vessels which constitutes the major cause of death in the Western world today [1]. 
Myocardial infarction (MI) and stroke are the main killers of this group, although 
peripheral vascular disease also plays a role. The main risk factors for CVD are genetic 
predisposition and smoking together with the components of the metabolic syndrome, 
which include hypertension, dyslipidaemia, obesity (abdominal) and decreased glucose 
tolerance (i.e. insulin resistance) (Fig. 1) [2]. The world-wide increase in obesity is a 
major contributor to the increasing prevalence of the metabolic syndrome and the 
changes in our life-styles that have occurred during the last decade are to blame [3]. 
The access to high-caloric food and drinks has increased in combination with sedentary 
occupations and leisure. In the US about 68 % of the population is reported to be 
overweight (BMI >25) and 34 % are obese (BMI >30) compared to 45 % and 13.5 % 
fifty years earlier. The corresponding numbers in Sweden today is 45 % overweight 
and 12 % obese, respectively [4]. Accordingly, the numbers of people developing type-
2 diabetes are increasing throughout the world and these individuals are at higher risk 
of developing CVD. The fact that the prevalence of obesity and type-2 diabetes is 
increasing in children and adolescents is also alarming, both from a socioeconomic and 
public health point of view [5]. 
 
     
 
 
 
 
 
Figure 1. The central role of the metabolic syndrome in vascular disease 
Multiple environmental and genetic factors contribute to the formation of the metabolic syndrome marked by 
hypertension, dyslipidemia, obesity and insulin resistance. These risk factors in turn contribute to initiation and 
progression of type-2 diabetes and the macrovascular diseases, i.e. myocardial infarction, stroke, and 
peripheral vascular disease. (Adapted from Razani et al. 2008) 
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1.1.1 Lipoprotein metabolism 
To understand the mechanisms for development of CVD, a brief introduction to the 
metabolism of lipids in the body is necessary. Dietary lipids are transported between 
the tissues of the body in the bloodstream as lipoprotein particles (Fig. 2) [6], which 
consist of a core of lipid surrounded by a shell of phospholipids and apolipoprotein, 
proteins specific for the destination of the lipoprotein particles. The lipoprotein particles 
include the chylomicrons (CM), very low density lipoproteins (VLDL), low density 
lipoproteins (LDL) and high density lipoproteins (HDL) and they all have specific 
compositions of lipids and apolipoproteins [7]. The lipoprotein metabolism is involved 
in determining the concentration of lipids in plasma and thus influences the amount of 
fat accumulation in tissues and arteries over a life span. Imbalance between production 
and removal of plasma lipids affects the homeostasis of the system and results in 
diseases caused by arterial lipid accumulation, such as atherosclerosis. Genes encoding 
for transcription factors that regulate proteins involved in the lipoprotein metabolism 
are central for the homeostasis of this system [8].  
    
 
 
 
Dietary lipids are degraded by pancreatic enzyme, subsequently absorbed by the 
intestinal mucosa cells and packed into the CMs. The CMs mainly contain triglycerides 
(TG) and some cholesteryl esters (CE) in the lipid core, and the apolipoprotein B48 in 
the outer shell. The CMs are released into the blood stream and the TGs in the particles 
are hydrolyzed into free fatty acids by the enzyme lipoprotein lipase (LPL), which is 
Figure 2. Schematic overview of the lipoprotein metabolism 
Simplified overview of the lipoprotein metabolism showing the major lipoproteins and 
their routes. See text for details. (Adapted from Enkhmaa et al. 2010) 
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located on the surface of the endothelium in the tissues. The fatty acids are taken up 
primarily by skeletal muscle and adipose tissue and the CM remnants, which are 
enriched in CEs, are recycled by the liver. The liver produces and secretes VLDL 
particles, which consist primarily of TGs but also CEs, and they are labeled with the 
apolipoprotein B100. The function of VLDL is to provide the peripheral tissues with 
lipids, just like the CMs. As the VLDLs move through the circulation, they are depleted 
of triglycerides and enriched in cholesterol and become so called LDL particles. The 
LDL particles provide the tissues with cholesterol and are considered to be atherogenic.  
On the contrary, the HDL particles are responsible for the reverse cholesterol transport 
which means that HDL delivers cholesterol back to the liver, where it can be further 
metabolized and excreted as bile. The HDL particles are synthesized by the liver and 
they mainly contain the apolipoproteins A-I and A-II. These particles can interact with 
cholesterol transporters on the surface of cells in the periphery; ABCA1 in 
macrophages and ABCG1 in endothelial cells, which loads them with cholesterol. As 
the HDL particles return to the liver they are captured by the scavenger receptor B, 
class 1 receptors (SRB1) [9]. The antiatherogenic function of apoA-I is established, 
whereas the role of apoA-II has been more debated [10]. The effects of PPARD 
activation on apoA-II expression will be investigated in paper I. 
 
1.1.2 Atherosclerosis 
Atherosclerosis is the underlying reason for development of CVD. It is a process 
resulting in the formation of a lipid-rich plaque in large and medium-sized elastic and 
muscular arteries, which in case of rupture causes sudden thrombotic occlusion of the 
artery at the site of disruption (Fig. 3) [11]. In the heart, atherosclerosis can lead to 
myocardial infarction, whereas in the arteries of the brain, it can cause ischaemic 
stroke. Furthermore, atherosclerotic lesions in other arterial branches, might result in 
renal impairment, hypertension and critical limb ischaemia [12, 13]. The 
pathophysiology of atherosclerosis in not totally understood, but it involves the 
formation of lesions in the arteries which are characterized by lipid accumulation, 
inflammation, cell death and fibrosis. The fatty streaks are the earliest signs of lesions 
and they are present in the arteries already early in life and with increased age these 
fatty streaks might develop into atherosclerotic plaques [14]. A major risk factor to 
develop CVD is dyslipidaemia, characterized by elevated triglyceride levels, high 
levels of circulating LDL cholesterol, and low levels of HDL cholesterol [15]. The 
LDL cholesterol, especially the small dense LDL particles [16], accumulate in the 
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intima of the arterial vessels where they are oxidized, which induces endothelial 
expression of adhesion molecules such as vascular cell adhesion molecule 1 
(VCAM-1) [17, 18]. These molecules attract monocytes from the blood stream to enter 
the intimal part of the artery, where they differentiate into macrophages under the 
influence of macrophage colony-stimulating factor (M-CSF) produced by endothelial 
cells and smooth muscle cells [19], and start expressing scavenger receptors [20]. The 
monocytes and macrophages belong to the innate immunity, the first line of defense of 
the body, and the scavenger receptors on macrophages detect oxidized LDL and 
promote their phagocytosis. As the disease progresses, the macrophages are overloaded 
with cholesterol, and turn into foam cells that start to produce inflammatory molecules 
which initiate an inflammatory response of the adaptive immunity, recruiting T-cells 
into the plaque. Activated T-cells produce inflammatory cytokines including 
interferon γ (IFNγ) and tumour necrosis factor α (TNFα), which leads to further 
activation of macrophages and endothelial cells [12]. The activated macrophages 
produce additional IFNγ and TNFα, as well as matrix-degrading enzymes, matrix 
metalloproteinases (MMPs), and reactive oxygen species (ROS). IFNγ and TNFα 
inhibit smooth-muscle-cell proliferation and collagen production, which increases the 
vulnerability of the plaque and hence the risk of rupture [21]. The MMPs further 
destabilize the plaque by degradation of the protective collagen and elastin [22], 
whereas the ROS contribute to oxidative modification of LDL and oxidative damage 
of DNA [23]. Furthermore, TNFα inhibits the enzyme LPL, leading to 
hypertriglyceridemia, which also promotes atherogenesis [24]. 
 
         
Figure 3. Simplified illustration of the initiation and progression of the atherosclerotic plaque 
The importance of macrophages in the atherosclerotic process is emphasized. See text for details.   
(Adapted from www.invivo.ca/illustration_and_print_formation_of_atherosclerosis.html) 
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1.1.2.1 Macrophages in atherosclerosis 
Recently, different macrophage subsets have been identified in the atherosclerotic 
lesions, which are important for the inflammatory status of the plaque. The 
“classically activated” M1 macrophages are induced by LPS and Th1 cytokines, 
mainly IFNγ, and they produce inflammatory mediators, such as IL-6 and TNFα. In 
contrast, the “alternatively activated” M2 macrophages develop as a response to the 
Th2 cytokines IL-4 and IL-13 and they secrete antiinflammatory mediators, such as 
transforming growth factor beta (TGFβ) and IL-10, to dampen the inflammatory 
response [25]. Both macrophage subpopulations are expressed in atherosclerotic 
lesions and modulate the inflammatory response, thereby they might have an impact 
on plaque stability and hence risk of development of CVD [26]. However, there is a 
plasticity between the subtypes and activated M1 macrophages can be modulated into 
M2 macrophages by expression of Th2 cytokines and vice versa [27]. It has been 
shown that expression levels of PPARG in atherosclerotic lesions are correlated with 
M2 markers, suggesting that PPARG plays a beneficial role in atherosclerosis by 
regulating macrophage subclasses. Also, PPARG activation primes human primary 
monocytes into the alternatively activated phenotype [26]. Accordingly, myeloid 
specific deletion of PPARG in mice impairs alternative activation and predisposes 
these animals to development of diet-induced obesity, insulin resistance, and glucose 
intolerance [28]. Additionally, the PPAR family member PPARD might be a major 
determinant of macrophage subtype activation as its expression is essential for 
alternative activation of resident macrophages in the liver and adipose tissue [29, 30]. 
Loss of PPARD expression in the macrophages in these tissues results in insulin 
resistance and obesity, respectively. However, a recent report did not show any 
correlation between PPARD mRNA expression and M2 markers in human 
atherosclerotic lesions [31] and this subject will be further investigated in paper IV. 
 
1.1.3 Drugs in the treatment of CVD 
 
1.1.3.1 Drugs in the treatment of dyslipidaemia 
It has been concluded that the most important and cost-effective interventions for the 
atherogenic lipid phenotype are an appropriate diet, weight loss, exercise, and 
smoking cessation [32]. In addition, there are pharmacological agents that can improve 
the metabolic profiles in already affected individuals. Most of the drugs in use today 
have effects on lowering of LDL cholesterol, since it has been considered the most 
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important parameter of the atherogenic dyslipidaemia [33]. However, low plasma HDL 
cholesterol has also been recognized as an independent risk factor of CVD and should 
be treated in addition to the LDL cholesterol [34-36]. Statins are the drugs of first 
choice for patients with high plasma concentrations of cholesterol commonly observed 
in dyslipidaemia, CVD, type-2 diabetes and other high risk states of atherosclerosis. 
Statins are primarily LDL cholesterol lowering agents and inhibit 
hydroxymethylglutaryl-CoA reductase, which catalyses the rate-limiting step in the 
endogenous cholesterol synthesis [33]. However, there are compounds which can be 
used as alternative drugs if statins are not well tolerated or in combination with statins 
if the desired effect is not achieved. The fibrates are drugs that activate PPARA in 
muscle, liver, and other tissues. They mainly decrease hepatic VLDL secretion and 
therefore plasma triglycerides, but fibrates also decrease the levels of LDL cholesterol 
in individuals with elevated baseline plasma LDL concentrations and increase HDL 
cholesterol levels in patients with low baseline plasma concentrations of HDL [37, 38]. 
Nicotinic acid (also known as Niacin) decreases both LDL cholesterol and 
triglycerides and it is the strongest HDL raising drug in clinical use at the moment. 
However, the main limitation for the use of nicotinic acid is its low tolerability, as it 
causes flush in almost every patient [33]. In addition the anion exchange resins, 
cholesterol absorption inhibitors and omega-3-fatty-acids are all compounds that can 
be used as combination therapies together with statins, however the effects on 
cardiovascular end-points are not established for the two latter ones. Large ongoing 
trials address the decisive question whether treatment with fibrates and niacin 
provides additional cardiovascular risk reduction when given in addition to statin 
treatment [33]. 
 
1.1.3.2 Drugs in the treatment of type-2 diabetes 
In order to control glucose levels in type-2 diabetes patients, the first line of drugs 
have been metformin and sulfonylureas. Sulfonylureas increase the secretion of 
insulin from the pancreatic beta cells [39] whereas metformin has been identified as 
an activator of AMP kinase, reducing glucose output from the liver and increasing the 
peripheral glucose utilization, in addition to its direct vascular effects [40]. The 
thiazolidinediones (TZDs) or glitazones are PPARG agonists which increase insulin 
sensitivity due to the uptake of free fatty acids from the circulation by the adipose 
tissue [41]. In addition there are some new insulin sensitizing drugs out on the 
market, which will not be discussed in this thesis.  
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1.1.3.3 Hepatotoxicity 
One of the most common reasons for stopping the development of promising drug 
candidates is hepatotoxicity discovered during preclinical studies. Furthermore, 
nearly 50% of all drugs fail in the post-marketing phase due to unexpected toxicity or 
unwanted interference with metabolism issues [42]. Since the introduction into 
clinical monitoring some 50 years ago, serum alanine aminotransferase (ALT) has 
become the standard biomarker for detection of liver injury [43]. ALT activity has 
been detected mostly in liver tissue [44] and ALT in serum is believed to be due to 
leakage from damaged hepatocytes. Serum aspartate aminotransferase (AST) activity 
is considered a less specific biomarker of liver function compared to ALT, since AST 
is present to a higher degree in skeletal and cardiac myocytes than in hepatocytes 
[45]. Elevations in ALT activity show high correlations to liver damage caused by drug 
toxicity, infection, alcohol, cirrhosis and inflammatory steatosis, and ALT activity is 
usually between 10-100 times higher than normal levels in these states [46]. However, 
the function of ALT as a perfect liver injury marker has recently been questioned [47].  
While it is true that the liver is the most ALT rich organ, ALT is also found at high 
concentrations in kidney, cardiac and skeletal muscle [48]. Furthermore, ALT is an 
important enzyme for gluconeogenesis and amino acid metabolism in humans (Fig. 4) 
[49]. Approximately 10% of the patients taking fenofibrate show increased 
aminotransaminases above normal levels. Despite this, there has been no reports of 
hepatic pathologies with fenofibrate use [50, 51] and in 1998, Edgar et al suggested 
that fibrates could increase the gene expression of ALT as an alternative “non-toxic” 
mechanism for the elevation of ALT enzymes in serum [46]. The normal turnover of 
hepatocytes, releasing their increased amounts of intracellular aminotransferases, 
would be the reason for the mild increase in serum ALT observed after treatment with 
fibrates. The subject of a possible PPAR-mediated regulation of the ALT1 gene will 
be investigated in paper II in this thesis.  
 
                                                               
Figure 4. Schematic overview of the 
glucose-alanine cycle catalysed by 
the enzyme ALT 
ALT is responsible for transamination of 
amino acids in the muscle and for 
gluconeogenesis in the liver. The amino 
groups transported from the muscle to 
the liver are converted into urea which 
is excreted in the urine. (Adapted from  
www.themedicalbiochemistrypage.org)  
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1.2 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS  
Peroxisome proliferator-activated receptors (PPARs) belong to the superfamily of 
nuclear receptors (NRs) which contain transcription factors that regulate the 
expressions of genes involved in processes such as reproduction, development and 
general metabolism. There are 48 members of the NR superfamily in humans and 49 in 
the mouse [52] and they all share a common structure. The PPARs are classified as 
members of group C in the nuclear receptor subfamily 1 (NR1C) [53] and they belong 
to a functional subgroup of the nuclear receptors denoted adopted orphan receptors 
(Fig. 5) [54]. 
        
 
  
 
PPARA (NR1C1) was the first member of the PPAR family to be discovered in the 
early 1990s [55] and obtained its name from the fact that it could bind agents that 
caused peroxisome proliferation in rodents. PPARB (NR1C2) and PPARG (NR1C3) 
were identified a few years later in Xenopus [56] and subsequently murine PPARG and 
one more paralogue which was named PPARD were identified [57]. However, when 
the chicken PPARB was cloned and characterized, it was evident that murine PPARD 
was the ortholog of xenopus PPARB and hence this receptor is now referred to as 
PPARB/D. In this thesis it will exclusively be referred to as PPARD. The PPARs are 
Figure 5. Functional grouping of the nuclear receptor superfamily 
The PPAR subfamily belongs to the group of adopted orphan receptors and 
is indicated in the figure with an arrow. (Adapted from Chawla et al 2001) 
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expressed by separate genes on different chromosomes and they are expressed in a 
tissue-specific manner.  
 
1.2.1 Structure 
All the nuclear receptors share a common structure which makes them able to bind to 
DNA and exert their functions as regulators of gene transcription (Fig. 6) [54]. The N-
terminal ligand-independent activating function 1 (AF-1) domain is the most variable 
between the PPAR family members, and it is recognized by coactivators and is 
considered to be important for transactivation and transcription [58]. The DNA-binding 
domain (DBD) is very well conserved and it is constituted by two highly conserved 
zinc finger-like structures which are responsible for receptor binding to its specific 
DNA sequences, the PPAR response elements (PPRE), and it also plays a role in 
dimerization [59]. The hinge region (H) permits protein flexibility to allow 
simultaneous receptor dimerization and DNA binding [54]. The ligand binding domain 
(LBD) consists of 12 α-helices (H1-12) which together constitute a pocket for the 
ligand. The entrance to the pocket is guarded by H12, which contains residues that are 
crucial for the function of AF2. In the absence of ligand, corepressors are bound to H3 
and H4 but when a ligand is bound, H12 induces a conformational change in the 
receptor and the corepressors are released. Instead, coactivators which contain LxxLL-
like motifs (where L is leucine and x is any amino acid) can bind to a hydrophobic cleft 
formed by H3, H4 and H12 which supports coactivator interaction and gene 
transcription. The LBD is also essential for dimerization. [60] 
 
 
 
 
 
 
 
1.2.2 Cofactors 
The nuclear receptors need additional proteins called cofactors to be able to exert 
their functions. The nuclear receptor cofactors include corepressors, coactivators and 
their associated proteins, and over 300 of them have been identified [61]. The 
coactivators directly bind to transcription factors and positively regulate target gene 
Figure 6. Schematic representation of the functional domains of PPARD 
The N-terminal domain contains the activation function 1 (AF-1).  DBD = DNA-binding 
domain, H = hinge region, LBD = ligand-binding domain. Amino acid (aa) numbers are 
shown above the receptor. (Adapted from Ehrenborg and Krook 2009) 
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transcription, either by modification of histone and chromatin structure to open up 
DNA for transcription, while others provide linkage to the core basal transcriptional 
machinery. CBP/P300 and SRC-1 are examples of coactivators which have been 
shown to associate with the PPARs and they loosen up the chromatin structure to 
enable transcription by possessing histone acetylace transferase (HAT) activity [62-
65]. The corepressors inhibit target gene transcription by recruitment of histone 
deacetylases (HDACs) to enforce a tight chromatin structure and classical examples 
are NCoR and SMRT [66, 67]. As far as is known, there are no receptor specific 
coactivators that direct the overall transcriptional activity of particular members of 
the PPAR subfamily [68]. In the absence of ligand, the PPARs are maintained in the 
nucleus in a repressed state by nuclear receptor corepressors such as NCoR and 
SMRT [69-71]. PPARD is the only PPAR subtype which is able to bind DNA when 
bound to corepressors and it can thereby repress PPAR target genes in the absence of 
ligand [69, 70, 72]. Another mechanism of gene repression exerted by PPARD is its 
association with BCL-6, which functions as a corepressor for genes involved in 
inflammation [73]. In the unliganded state, PPARD binds to and sequestrates B-cell 
lymphoma 6 protein (BCL-6), whereas ligand binding causes BCL-6 dissociation and 
repression of inflammatory genes. Binding of a ligand to a PPAR results in the 
dissociation of the corepressors and then an orchestrated recruitment of several 
transcriptional coactivators which facilitates gene transcription. Besides ligand 
binding, activation or repression of target genes by the PPARs also depends on the 
cellular expression pattern of coactivators and corepressors, as has been taken 
advantage of in the SPPARM concept (described in section 1.2.6.2) [74].  
 
1.2.3 Function 
The PPARS are lipid sensors with distinct but overlapping functions in glucose and 
lipid metabolism. The natural ligands for all the PPARs are unsaturated fatty acids and 
their derivatives. Upon ligand binding the PPARs heterodimerize with the retinoid X 
receptor (RXR) and bind to PPRE which consists of a direct repeat (DR) of the 
consensus sequence AGGTCA separated by one nucleotide, called a DR1 motif [75] 
(Fig. 7) [58]. It has been reported that the 5'-flanking region to the PPRE is responsible 
for subtype specific activation of the PPARs [76]. The conformational change induced 
by ligand activation releases corepressors and allows coactivators to bind, which 
induces transactivation and transcription. 
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1.2.4 PPARA 
The human PPARA gene consists of eight exons and it is localized at chromosomal 
region 22q12-q13.1 [77, 78]. PPARA is primarily expressed in tissues with a high 
level of fatty acid metabolism such as liver, skeletal muscle, heart, kidney, and intestine 
[79]. The major role of PPARA is the regulation of energy homeostasis and mainly in 
the liver, PPARA activates fatty acid catabolism, stimulates gluconeogenesis and 
ketone body synthesis [80, 81]. The function of PPARA in hepatic fatty acid 
metabolism is especially prominent during fasting and in normal mice, PPARA 
expression increases during fasting. In contrast, fasted PPARA knock-out mice have 
fatty livers and elevated levels of free fatty acids in plasma due to the inability of the 
liver to oxidize the fatty acids released from adipose tissue [81]. Furthermore, fasted 
PPARA null mice show decreased levels of plasma glucose and ketone bodies due to 
decreased gluconeogenesis and lipid oxidation, respectively. In addition, the starved 
PPARA mice suffer from hypothermia [81]. An additional function of PPARA is to 
control the hepatic expression of enzymes involved in the control of amino acid 
metabolism and urea synthesis [82]. PPARA is also involved in the regulation of 
lipoprotein assembly in the liver, which is demonstrated by the capacity of the PPARA 
activating fibrates to increase the expression of apolipoproteins involved in the reverse 
cholesterol transport [83-85]. PPARA has also been described to be a modulator of 
inflammation by negative crosstalk with the NFκB pathway and treatment of 
hyperlipidemic patients with fibrates is shown to decrease the elevated levels of TNFα 
and IFNγ [86-88].  
Figure 7. PPAR ligand binding, dimerization and transactivation  
Upon ligand binding the PPARs form heterodimers with RXR and bind  
to PPRE in gene promoters. The effects are further modified by interaction 
with specific cofactors. Fatty acid binding proteins (FABP) may bind and  
deliver ligands to the receptor. (Adapted from Ehrenborg and Krook, 2009) 
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1.2.5 PPARG 
The human PPARG has nine exons and is located on chromosome 3p25 [89]. The 
human PPARG gene gives rise to three different transcripts due to alternative promoter 
usage (PPARG1-3) but after alternative splicing of the 5' -end of the transcripts, 
PPARG1 and 3 gives rise to the same protein, hence there are two protein isoforms of 
the human PPARG (PPARG1 and PPARG2) [90]. The functional difference between 
the isoforms is not clearly understood but PPARG2 expression is restricted to adipose 
tissue where it seems to play a major role in adipocyte differentiation, whereas 
PPARG1 is more widely expressed. Adipose tissue, large intestine, and hematopoietic 
cells express the highest amounts of PPARG1 while kidney, liver, and small intestine 
have intermediate levels. PPARG3 is abundant in macrophages, the large intestine 
and white adipose tissue [90].The function of PPARG is to induce adipocyte 
differentiation and increase the expression of genes involved in lipogenesis [91]. 
Furthermore, PPARG is involved in the glucose metabolism through an improvement 
of insulin sensitivity, when fatty acids are taken up from the circulation. Lately 
PPARG has also been recognized to play an important role in inflammation, 
favouring a more antinflammatory phenotype of the residential macrophages in 
adipose tissue and liver [28].  
  
1.2.6 PPARD 
Human PPARD is located at chromosomal region 6p21.2-p21.1 and comprises nine 
exons [92]. PPARD is ubiquitously expressed and its function was an enigma for a 
long time. It is the least studied of the three PPAR subtypes due to its ubiquitous 
expression and unavailability of selective ligands [93]. However, during the last 
decade it has received more attention and its role in energy homeostasis and fatty acid 
catabolism has been recognized since the specific ligand GW501516 was synthesized. 
Administration of GW501516 to mice increases oxidation of fatty acids in the skeletal 
muscle and ameliorates diet-induced obesity and insulin resistance [94]. In insulin 
resistant rhesus monkeys, treatment with GW501516 showed decreased plasma 
triglyceride and LDL cholesterol levels, especially the small dense LDL particles, as 
well as increased plasma HDL levels. Additionally, the insulin levels of the monkeys 
were decreased by treatment with the PPARD agonist [95]. The importance of PPARD 
for lipid metabolism has also been demonstrated by transgenic tissue-specific 
expression in mice. Transgenic expression of an activated form of PPARD in adipose 
tissue results in lean mice which are resistant to obesity induced by a high-fat diet 
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[96]. In parallel, muscle-specific PPARD overexpression results in a shift to more 
oxidative muscle fibers (type 1), increased expression of genes involved in oxidative 
metabolism and reduced body fat mass [97]. Also, endurance exercise promotes an 
accumulation of PPARD protein in muscle of wild-type mice and transgenic mice 
overexpressing the activated form of PPARD in skeletal muscle, are lean and show 
increased endurance and expresson of oxidative fibers compared to their wild-type 
littermates [97, 98]. The beneficial role of PPARD on lipid metabolism makes it a 
plausible target for treatment of obesity and insulin resistance. Studies in mice also 
reveal the importance of PPARD in the embryonic development, in the skin, brain 
and in the regulation of inflammatory macrophages in liver and adipose tissue [29, 
30, 99, 100].  
 
1.2.7 Ligands 
 
1.2.7.1 Endogenous ligands 
All the PPARs have wide ligand-binding pockets compared to the other members of the 
nuclear receptor family, which makes them able to bind fatty acids and their 
derivatives. Hence, the natural ligands for all the PPARs consist of polyunsaturated 
fatty acids (PUFAs), such as linoleic, linolenic and arachidoinc acid [101]. However, 
there are some differences in ligand preference between them; the ligand binding cavity 
in PPARA is more hydrophobic than the other two PPARs, which explains why it also 
can accommodate saturated fatty acids. In contrast, PPARD is shown to have a 
narrower pocket compared to PPARA and PPARG, which explains why it is more 
restrictive in binding saturated fatty acids [102]. Furthermore, some eicosanoids can 
serve as subtype specific ligands, for example leukotriene B4 can activate PPARA 
whereas 15-Deoxy-D12,14-PGJ2 has been identified as a more specific ligand for 
PPARG [101]. In contrast, the fatty acid erucic acid (C22:1), which is a weak ligand, 
appears more selective for PPARD [103]. In addition to ligand specificity, there are 
intracellular lipid binding proteins, so called fatty acid binding proteins (FABP) 
which bind ligands specific for the different PPAR isoforms and bring them into the 
nucleus of the cell where the PPARs are located. Interestingly, although FABP4 and 
FABP5 bind multiple ligands, only particular compounds trigger their nuclear 
translocation [104]. FABP4 moves into the nucleus in response to ligands that 
activate PPARG but not upon treatment with PPARD ligands. In contrast, FABP5 
mobilizes to the nucleus only in response to ligands that activate PPARD [105]. 
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1.2.7.2 Synthetic ligands 
Because of their central role in the regulation of genes involved in energy 
homeostasis and inflammation, PPARs have become attractive pharmaceutical targets 
for the treatment of metabolic disease. The fibrates activate PPARA and the use of 
fibrates in the management of lipoprotein disorders has a history dating 
back to the mid-1960s [106]. They show few significant side-effects and are 
considered to be relatively safe, but have been associated with muscle weakness, 
myopathy and in some rare cases rhabdomyolysis [107]. The glitazones are synthetic 
ligands for PPARG and were introduced on the market at the end of the 1990s and 
they are associated with weight-gain, fluid-retention and an increased risk of bone 
fracture [108-110]. Since the withdrawal of Troglitazone in the year 2000 due to 
hepatotoxicity [111] and now the recent withdrawal of Rosiglitazone from the market 
in 2010 due to the increased risk of MI, stroke and overall mortality [112, 113], the 
safety concerns of PPARG agonists have been raised. Regarding PPARD specific 
agents, no compounds are in clinical use yet, but there are some small recent human 
studies that have evaluated the short-term effects of GW501516 [114, 115]. Both 
studies showed decreased triglyceride levels after two weeks treatment despite the 
fact that the participants were healthy and only moderately obese. Increased HDL-
levels was only obtained in one of the studies [114] whereas decreased LDL 
cholesterol and increased insulin sensitivity was observed in the other one [115]. 
However, GlaxoSmithKline, the company in charge of GW501516, terminated a 
phase I trial with this compound in 2005 and it is no longer on their list of compounds 
in the pipeline [116]. Another synthetic PPARD agonist, MBX-8025, from the 
company Metabolex showed decreased triglyceride and LDL cholesterol and 
increased HDL cholesterol in an eight week long study including 173 obese or 
overweight participants [117]. Considering the side-effects of some PPARG agonists, 
which have been out on the market for years, there is already reluctance towards 
PPAR compounds and it is obvious that any drug acting via PPARs needs to 
demonstrate a favorable cardiovascular risk-benefit profile. Dual PPARA/G agonists 
and pan-PPARA/G/D agonists have been developed in hopes of achieving multiple 
therapeutic benefits but reducing the side-effects [118]. However, the safety is still an 
issue for these agents. Another type of second generation PPAR compound is the 
selective PPAR modulators (SPPARMs) which are designed to activate the PPARs in 
a tissue-selective manner [74]. Hence, only desirable effects of PPAR activation are 
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achieved whereas side-effects can be avoided. The SPPARMs bind to the PPAR and 
induce a conformational change in the LBD distinct from when a full agonist is 
binding, resulting in preferential binding of specific cofactors or corepressors. Thus, 
differential PPAR effects can be achieved depending on tissue expression of distinct 
sets of coactivators and corepressors. The SPPARγMs show good efficacy and less 
side-effects in pre-clinical animal models of metabolic disease and it remains to see 
how well they perform in clinical trials [74].  
 
1.3 PPAR REGULATION 
So far, the main focus of PPAR research has been to unravel the effects of activation of 
PPARs whereas considerably less is known about the regulation of their expression 
[119]. Most research has been performed using mice models, which means that the 
regulatory mechanisms between humans and mice might deviate. However, keeping 
that in mind, the main mechanisms of regulation of the PPARs will be summarized 
below and an overview of these mechanisms is shown in Figure 8. 
 
 
 
 
Figure 8. Schematic overview of the main mechanisms of PPAR regulation 
The levels of regulation are depicted on the left hand side and the mechanisms of regulation are 
described on the right hand side of the figure. The figure is based on the PPARD gene, since it is the 
main focus of this thesis, even though the mechanisms are valid for all the PPAR family members.  
The transcriptional start of the PPAR gene is indicated with an arrow and +1. 
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1.3.1 Transcriptional regulation  
Since there is not much data regarding the transcriptional regulation of the PPARs, the 
main focus of this chapter will be on the posttranscriptional regulation of the PPARs. 
However, it can be mentioned that a recent study identified differential binding of 
estrogen-related receptor (ERR) α and γ to a site encompassing a single nucleotide 
polymorphism (SNP) in the human PPARA promoter, which influences the 
transcriptional activity of the gene [120]. Furthermore, adipogenic hormones such as 
insulin and glucocorticoids induce PPARG transcription during early adipogenesis 
through the CCAAT enhancer-binding proteins [121]. Also, the SREBP1 and -2 
directly control the expression of the human PPARG gene [122]. In silico analysis of 
the human PPARD promoter showed that it lacks a TATA box but is rich in potential 
Sp-1 binding elements, which is a typical feature for house-keeping genes, and it also 
contains two putative NFκB elements [92]. 
 
1.3.2 Post-transcriptional regulation 
 
1.3.2.1 Alternative splicing 
Splicing of precursor mRNA (pre-mRNA) is a crucial regulatory step in the pathway 
of gene expression. The mature mRNA is formed as the introns of the pre-mRNA are 
removed and the exons are ligated together (Fig 9) [123]. Splicing occurs in 
organisms ranging from yeast to human and take place within the spliceosome, a 
large protein complex containing the small nuclear RNAs (snRNAs) U1, U2, U4, U5 
and U6, and more than 100 core proteins [124, 125] (Fig 9B) [123].  
 
Four signals located at the exon-intron boundaries have a well characterized role in 
helping directing the splicing machinery. In the 5'-end of the intron, the 5' splice site 
denoted by the nucleotides GU in the exon/intron boundary encompassed within a 
larger less conserved sequence. In the 3'-end of the intron, there is the branch point 
containing an adenosine, a polypyrimidine tract (PPT), followed by a terminal AG 
[126] (Fig. 9A). In addition, there are short conserved regions in the exons and 
introns which act as exonic or intronic splicing enhancers or silencers. Specific 
binding of splicing regulatory proteins called SR proteins to these regulatory regions 
assists in the positioning of the spliceosome on the appropriate splice sites [127, 128].  
   17 
 
Alternative splicing, which includes different exons in the mRNA, results in the 
generation of alternative isoforms and is often tightly regulated in a cell-type- or 
developmental stage-specific manner [129]. There are several different types of 
alternative splicing events (Fig. 9C) of which exon skipping is the most common in 
higher vertebrates, followed by alternative 3'- and 5'-splice site (SS) selection, and 
intron retention [130]. Also, more complex events like mutually exclusive exons, 
alternative promoter usage and alternative polyadenylation give rise to alternatively 
spliced transcripts in vertebrates [131].  
 
 
 
 
 
 
Dominant negative regulation by truncated receptor isoforms has been described for 
many of the members of the nuclear receptor superfamily, such as the glucocorticoid 
receptor, estrogen receptor and vitamin-D receptor [132-134]. Both the PPARA and 
PPARG genes have been shown to express truncated isoforms by alternative splicing, 
which act as dominant negative regulators of their respective full-length receptor [135, 
136]. The truncated isoforms lack a part of the ligand-binding domain, which makes 
them unable to bind ligands, and they are expressed at low levels compared to the full-
length variants. Alternative splicing for the human PPARD gene has not been studied, 
even though a truncated version has been reported in the NCBI database. In paper III, 
the putative regulation of PPARD by alternative splicing is investigated. 
 
Figure 9. Schematic overview of the mechanisms of splicing  
A) The four conserved signals that enable recognition of RNA by the spliceosome are shown 
above. B) The splicing machinery that performs the main steps in the splicing process is shown. 
C) Different types of alternative splicing events. SS = splice site; PPT = polypyrimidine tract.  
(Adapted from Keren et al 2010) 
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1.3.2.2  MicroRNA 
MicroRNAs (miRNAs) are endogenous non-coding single-stranded RNAs 
approximately 22 nucleotides long that bind to their target mRNA and either induce 
mRNA degradation or inhibit protein translation [137]. They are expressed from 
animals to plants, are conserved between species and are implicated in diverse 
biological processes such as development and differentiation [138]. Furthermore, many 
of them have been reported to be aberrantly expressed in different forms of cancers 
[139]. In mammals, more than 50% of mRNAs are predicted to be the subject of 
miRNA-mediated control [140]. The miRNAs are initially transcribed in the nucleus 
bý RNA polymerase II as long primary transcripts (pri-miRNAs) which are capped 
and polyadenylated, and cleaved into 60-80 nucleotide hairpin structures (pre-
miRNAs) (Fig. 10) [141]. After the completion of the nuclear processing, the pre-
miRNA is exported into the cytoplasm by the nuclear transporter protein Exportin 5 
where it undergoes further processing by the Dicer, releasing ~22 nt miRNA duplexes 
containing ~2 nt overhands at either end. The strand with the least stable pairing in 
the 5'-end (the guide strand) is selectively loaded into the RNA-induced silencing 
complex (RISC) which targets transcripts through either mRNA cleavage or 
translational repression [142, 143]. The other strand (passenger strand or miRNA*) is 
degraded.  
   
The miRNAs:RISC complexes bind to and regulate their target mRNAs by partial 
complementary binding in the 3'- untranslated region (3'-UTR) of the mRNA. 
However, there are exceptions to this rule and some miRNAs have been reported to 
bind to the 5'-UTR or to the coding region of the mRNA [144-147]. Additional 
features of the target mRNA has shown to be of significance such as AU-rich 
elements and positioning of the sites within the 3'-UTR [148]. The most important 
part of binding is between nucleotide 2-8 from the 5'-end of the miRNA, the so called 
seed sequence [149, 150]. In addition, complementarity in the 3' end of the miRNA 
has proven to be of significance for increased stability of the binding and 
compensation of a weak seed region [150]. Another recently discovered group of 
miRNAs are the ones with centered pairing, which lack both perfect seed pairing and 
3'-compensatory pairing and instead have 11–12 contiguous Watson-Crick pairs to 
the center of the miRNA [151]. 
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Transcription factors are often subjected to miRNA regulation, which introduces an 
additional level for the cell to control its regulators. Of the human PPARs, both 
PPARA and PPARG have been shown to be regulated by miRNAs. PPARA protein 
expression is targeted by miR-519d in subcutaneous adipose, a miRNA which is shown 
to be highly expressed in severely obese compared to non-obese subjects [152]. MiR-
519d was also shown to increase lipid accumulation during preadipocyte 
differentiation, indicating that it plays a role in obesity. PPARG is targeted by miR-27 
and miR-130, which are downregulated during adipocyte differentiation [153-156]. No 
data are yet available regarding the regulation of PPARD by miRNA, however the 
question of whether PPARD is miRNA regulated will be investigated in paper IV.  
 
Figure 10. Biogenesis and function of miRNA  
The miRNAs are transcribed in the nucleus and delivered into the 
cytoplasm where they exert their effects on mRNA degradation or 
protein synthesis. See text for details.   
(Adapted from Chang and Mendell, 2009) 
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1.3.3 Post-translational regulation of PPARs 
 
1.3.3.1 Phosphorylation 
Both mPPARA and mPPARG are shown to be phosphorylated by various stimuli 
affecting the different domains of the receptors. For example, insulin activates MAPK 
which activates ERK leading to phosphorylation of the A/B domain in AF-1 containing 
N-terminus of the receptor, resulting in release of corepressors and increase in the 
transactivational activity of both receptors [157]. So far, less information is available 
regarding the phosphorylation of the PPARD isotype, even though there are sites 
predicted in the protein, which implies that PPARD also might be a phosphoprotein 
[158]. Furthermore, both cAMP and PKA activators are shown to increase both 
ligand-activated as well as basal activity of PPARD [159, 160]. 
 
1.3.3.2 Ubiquitination and sumoylation 
Ubiquitin is an 8 kDa protein which covalently binds to proteins to target them for 
degradation by the 26S proteasome. In vitro studies have shown that both PPARA 
and PPARG can be targeted for degradation by ubiquitination. Furthermore, PPARA 
agonists stabilize the receptor whereas the degradation of PPARG via ubiquitination 
is enhanced by ligand binding [161, 162]. For PPARD, in vitro studies show that 
under conditions of moderate expression, GW501516 is not significantly influencing 
ubiquitination or degradation of PPARD. In contrast, overexpression of PPARD via 
transient transfection dramatically enhances its degradation by ubiquitination and 
proteosomal degradation, which is inhibited upon ligand binding [163]. 
  
Small ubiquitin-like modifiers (sumo) compose a family of three 11 kDa proteins 
homologous to ubiquitin which can be reversibly conjugated to the lysine residues of 
proteins through covalent binding [164]. Many of the sumo-modified proteins 
identified to date are transcription factors, coactivators, or corepressors and in the 
majority of cases attachment of sumo appears to repress the activity of transcriptional 
activators [165]. So far, among the PPAR family members PPARA [166, 167] and 
PPARG [168] have been described to be regulated by sumoylation. Modification of 
PPARA by sumoylation specifically recruits the corepressor NCoR but not SMRT 
which might lead to differential expression of a subset of PPARA target genes. For 
PPARG, it is shown that ligand-dependent sumoylation directs the receptor to the 
promoter of the iNOS gene after inflammatory stimuli and induces its transrepression, 
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which explains the inhibitory effect of PPARG on some genes involved in 
inflammation [168]. 
 
It is obvious from this introduction that furthers studies regarding the regulation of the 
PPARs are needed, especially of PPARD. Furthermore, additional PPARD target genes 
implicated in metabolic disease remain to be identified. Clearly this receptor has its 
beneficial properties, even though its broad tissue expression might limit its potential as 
a drug target. Hence, this thesis will explore additional target genes of PPARD as well 
as further elucidate the mechanisms of its regulation. 
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2 HYPOTHESIS AND AIMS 
 
 
Hypothesis: 
 
The overall hypothesis for this thesis is that PPARD activation increases the expression 
of genes beneficial to prevent the development of atherosclerosis and CVD, and 
furthermore that the PPARD gene per se is subjected to regulation by 
posttranscriptional mechanisms. 
 
Aims: 
 
The general aims of this thesis were to identify human PPAR target genes and improve 
our understanding of the molecular mechanisms regulating the expression of human 
PPARD. 
  
Specific objectives 
 
• To characterize the mechanisms of PPARD activation on the apoA-II gene 
expression (paper I) 
• To determine whether the ALT genes are transcriptional targets of the PPARs 
(paper II) 
• To investigate whether PPARD is subjected to posttranscriptional regulation via 
alternative splicing and miRNA (paper III and IV) 
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3 MATERIALS AND METHODS 
 
Detailed descriptions of materials and methods are given in the individual papers. 
 
3.1.1 Chemicals (paper I-IV) 
The synthetic PPARD agonist GW501516 was synthesized by Synthelec AB as 
described [169]. Fenofibric acid was a kind gift from Professor Per Eriksson, 
Karolinska Institutet, Sweden. Additional fenofibric acid and AZD4619 were obtained 
from Astra Zeneca, Mölndal, Sweden. Rosiglitazone was obtained from Cayman 
Chemical Company and TNFα from Calbiochem. The cytokines used in paper IV were 
purchased from Peprotech and LPS from Sigma.  
 
3.1.2  Bioinformatic sequence analyses (paper I-IV) 
In order to find putative PPREs in the hypothesized target genes apoA-II and ALT1, the 
MatInspector program in the Genomatix database [170], the Alibaba 2.1 [171] and 
Promo [172] programs were used (paper I and II). To identify sequence conservation 
between species the ECR browser tool [173], and ClustalW [174] were utilized (paper I 
and III). Furthermore, the RepeatMasker [175] was used to look for repetitive elements 
in the PPARD gene. In paper IV, miRNA target site prediction was performed by the 
UCSC genome browser [176] (human May 2004 assembly), which includes miRNA 
target predicitions from the databases TargetScanS [177] and PicTar [178]. 
 
3.1.3 Cell culture (paper I-IV) 
A panel of human cell lines have been used in this thesis; the human hepatocellular 
carcinoma cell lines HepG2 and HuH-7, the human embryonic kidney cell line 
HEK293, the cervical epithelioid carcinoma cell line HeLa, and the kidney epithelial 
carcinoma cell line A498 were all maintained in DMEM (1 g/l glucose), containing 10 
% FBS, penicillin (100 U/ml) and streptomycin (100 μg/ml) at 37°C in 5 % CO2 in air.  
The monocytic leukaemia cell line THP-1 was maintained in RPMI using the same 
conditions as described for DMEM. Cryopreserved human hepatocytes from five 
different donors were obtained from In Vitro Technologies and were maintained in 
DMEM as described for the cell lines above (paper II). Human primary monocytes 
were purified from blood obtained from anonymous donors and were cultured in RPMI 
and 10 % human AB serum or differentiated into macrophages as described in next 
section (paper IV).  
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3.1.4 Monocyte isolation and macrophage differentiation (paper IV) 
Monocytes were purified from buffy coats obtained from unknown healthy blood 
donors by endotoxin-free Ficoll purification (Ficoll paque PLUS, GE Healthcare) 
followed by two steps of Percoll purifications (Percoll PLUS, GE Healthcare) as 
described in Repnik et al [179], which resulted in about 70 % CD14 positive cells, as 
determined by FACS analysis. The monocytes were seeded out in 6-well plates in 
RPMI containing 100 ng/ml M-CSF, 20% human AB-serum, penicillin (100 U/ml) and 
streptomycin (100 μg/ml). After 7 days, the monocytes had differentiated into 
macrophages and the medium was replaced with RPMI containing 10 % hAB serum 
and antibiotics as above (M0). To obtain M1 macrophages, 100 ng/ml LPS and 20 ng 
/ml IFNγ was also added to the fresh culture medium, whereas for M2, Il-4 was added 
at a concentration of 20 ng/ml. After 6, 24 and 72 hours, the cells were harvested for 
RNA using Qiazol or saved for FACS analyses. 
 
For the monocyte studies, the EasySep human monocyte enrichment kit (#19059, Stem 
Cell Technologies) was used straight after the Ficoll purification. The cells (>90 %  
CD14 positive cells as determined by FACS analysis) were seeded out at in 6-well 
plates in RPMI containing 10% human AB-serum, penicillin (100 U/ml) and 
streptomycin (100 μg/ml), in the presence or absence of 100 ng/ml LPS. The cells were 
harvested after 8 or 24 hours, using Qiazol (Qiagen) for subsequent analysis of total 
RNA, including miRNA. 
 
3.1.5 Flow Cytometry Analysis (paper IV) 
Differentiated macrophages (M0, M1 and M2) were incubated with APC 
(allophycocyanin)/Cy7-conjugated antibody CD206 (BioLegend). Analyses were 
performed using a CyAn ADP Analyzer flow cytometer and the Summit software 
(Beckman Coulter). 
 
3.1.6 DNA sequencing (paper I-IV) 
Sequencing was performed using a Big Dye Terminator Kit and an automatic 
sequencer (Genetic Analyzer 3100, Applied Biosystems) to control that all cloned 
constructs were correctly assembled and to verify the mutations introduced after in 
vitro mutagenesis.  
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3.1.7 Plasmids and expression vectors (paper I-IV) 
- Cloning of promoters was performed using PCR amplification,  followed by 
subcloning into the PCR 2.1 vector (Invitrogen) and subsequent transfer into the 
reporter gene vector pGL3basic (Promega) (paper I-III). Likewise, approximately two 
kb of the PPARD 3'-UTR was cloned into the psiCHECK2 vector (Promega) for 
subsequent use in the miRNA reporter assays. The 36 bp constructs covering the 
miRNA target sites of PPARD were obtained by annealing complimentary 
oligonucleotides for the sites and subsequent cloning into the psiCHECK2 vector 
(paper IV). 
- In vitro mutagenesis of putative PPREs or miRNA target sites was performed using 
oligonucleotides containing the desired mutations and a mutagenesis kit from 
Stratagene.  
- The expression vector for human PPARA was a kind gift from Eleanor S Pollak, 
University of Pennsylvania School of Medicine, PA, USA. The expression vector for 
PPARD was kindly provided by Dr. CN Palmer and is described elsewhere [180]. The 
PPARD expression vector was modified into PPARD2 by replacement of the 3'-end of 
PPARD1 with a PCR-product containing the 3'-end of PPARD2 (paper III). To obtain 
the full-length PPARD, the whole 3'-UTR of PPARD1 was inserted into the vector 
coding for PPARD1 (paper IV). 
- The TNT vector coding for PPARD was cloned as described above, using the full-
length sequence for PPARD. The TNT vectors for PPARA, PPARG and RXRA were 
all cloned by our collaborators at Astra Zeneca. 
- The miRNA expression vectors coding for either miR-9, miR-29 or miR-155 were 
created by PCR amplification of the genomic loci and subsequently cloned into the 
pcDNA 3.1/V5-His-TOPO, by our co-authors at CCK, Karolinska Institutet.  
 
3.1.8 Transient transfection and Luciferase assays (paper I-IV) 
For the reporter assays, the cells were seeded out in 24-well plates in PEST-free 
medium and the following day, the appropriate reporter constructs and expression 
vectors were added together with lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions. For the promoter studies, agonists or other compounds 
were added in fresh medium after 24 hours and the cells were treated for an additional 
24 hours, whereas the miRNA reporter assays were harvested after 24 hours of 
transfection. The cells were then lysed with a triton-X containing lysis buffer and the 
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luciferase activities of the lysates were measured in a luminometer (Lucy2, Anthos).  
For normalisation of the transfection efficiency, a β-galactosidase plasmid was 
cotransfected with the reporter plasmid and β-galactosidase activity was also measured 
(paper III). The psiCHECK2 vector used in paper IV contains the sequences coding for 
both renilla and firefly luciferase, hence no external normalisation plasmid was needed 
and a dual luciferase assay, measuring both renilla and firefly luciferase was run for 
these plasmids. In paper I and II, no normalisation was used for transfection efficiency, 
however, the transfections were repeated several times with similar results. 
 
3.1.9 RNA isolation, reverse transcription and quantitative real-time 
PCR (paper I-IV) 
Total RNA isolation was performed using the RNeasy system (Qiagen) and reverse 
transcription was performed on 350-1000 ng of total RNA using a poly-dT primer and 
Superscript II or III (Invitrogen) according to the manufacturer’s instructions. Real-time 
PCR was performed using gene-specific TaqMan assays (paper I, II, IV) or PPARD 
exon-specific primers and probes (paper III). The reaction conditions involved an initial 
denaturation step for 10 min at 95°C, followed by 45 cycles of amplification with 15 
sec at 95°C and 1 min at 60°C, using an ABI prism 7000 (Applied Biosystems). All 
samples were analysed at least in duplicates and the data was analysed using the 
comparative Ct-method.   
 
For miRNA detection, the miRNeasy kit (Qiagen) was used for isolation of total RNA. 
Reverse transcription was performed on 10 ng total RNA using specific primers for 
miR-9, miR-29 or U48 together with the TaqMan miRNA reverse transcription kit 
(Applied Biosystems). The cDNA was amplified by real-time PCR with the 
corresponding TaqMan miRNA assays (Applied Biosystems) according to the 
instructions, using the conditions described above. 
 
3.1.10 Coupled transcription/translation (paper I-III) 
Coupled in vitro transcription and translation was performed to determine relative 
protein expression from different mRNA species (paper III) and to obtain the proteins 
used in the EMSAs (papers I-III). The TNT Quick coupled Transcription/Translation 
system (Promega) was used together with 1 μg of the TNT plasmid and either 
[35S]methionine (Amersham) or unlabelled methionine according to the manufacturer’s 
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instructions. The translation products were subsequently separated by a 10 % SDS-
PAGE, subjected to autoradiography and analysed on a PhospoImager (paper II) or 
used in the EMSAs as described below. 
 
3.1.11 Western blot (paper II-IV) 
Whole cell extracts from primary hepatocytes treated with fenofibric acid (paper II) 
where subjected to Western blot analysis under reducing conditions as described by 
Laemmli [181], using an ALT1 specific antibody (paper II). Likewise, nuclear extract 
from HeLa cells transfected with PPARD1, PPARD2 or empty expression vector 
(paper III), or from monocytes treated with LPS or vehicle (paper IV), were subjected 
to Western blot analysis using a PPARD specific antibody, detecting the N-terminal 
part of the protein (sc-7197, Santa Cruz). Furthermore, in vitro translated PPARD from 
the different 5'-variants in paper III were subjected to Western blot analysis using an 
antibody detecting the C-terminal of PPARD (IMG 3297, Nordic Biosite). In paper IV, 
nuclear extracts from primary monocytes treated with LPS or vehicle for 24 hours were 
subjected to Western blot analysis, using precasted gradient gels 4-12 % (Criterion XT 
Bis-Tris Gels, BioRad) and the PPARD antibody sc-7197 (Santa Cruz). 
 
3.1.12 Electrophoretic mobility shift (EMSA) (paper I-III) 
EMSA was performed to study binding of the PPARs to putative PPREs (paper I and 
II) and also to study the binding of PPARD1 and PPARD2 to a classical PPRE (paper 
III). Double-stranded oligonucleotides corresponding to the putative PPREs, or to the 
classical rat acyl-CoA (ACO), were labelled with [γ-32P] and mixed with a buffer 
containing 2 μg poly(dI-dC), 0.75 mM EDTA pH 8.0, 18 mM HEPES pH 7.9, 0.5 mM 
dithiothreitol and 4 % Ficoll and in vitro produced PPAR and RXR in a molar ratio of 
3:1. For competition, 100-fold molar excess of unlabelled double-stranded 
oligonucleotide was added and for the supershift, the PPARD antibody sc-7197 was 
used. The mixtures were subjected to a 6 % polyacrylamide gel which was run 4h at 
200 V, dried and then analysed on a PhosphoImager.   
 
3.1.13 Chromatin immunoprecipitation (ChIP) (paper I-II) 
ChIP was performed to assess in vivo binding of PPARD to the promoters of apoA-II 
and ALT1 (paper I and II). HepG2 cells were treated with PPAR agonists for 8 hours 
and the DNA and protein were subsequently cross-linked using formaldehyde. The 
chromatin was purified, followed by enzymatic digestion and immunoprecipitation 
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using a PPARA, G and D antibody, respectively, or a control IgG. Immunoprecipitated 
DNA was subjected to PCR with primer pairs specific to the putative PPREs in apoA-II 
and ALT1, respectively, whereas primer pairs amplifying regions further downstream 
were used as negative controls. Chromatin input was used as a positive control while 
H20 was used as blank control templates for both primer pairs.  
 
3.1.14 Rapid amplification of cDNA ends (RACE) (paper II) 
Both 5'- and 3'-RACE were performed to identify possible alternative 5'-ends in 
transcripts of PPARD and to study alternative 3'-splicing. Marathon cDNA from 
placenta, adipose tissue and pancreas (Clontech) were used together with the adapter 
primers AP1 and AP2, together with combinations of PPARD-specific primers. Two 
sequential rounds of either 5'- or 3'-RACE were carried out and subsequently the 
obtained PCR products were purified and sequenced. Additional rounds of nested PCR 
were performed with the AP2 primer and exon-specific PPARD primers in order to 
enrich for transcripts expressed at low levels.  
 
3.1.15 Human subjects (paper II) 
The clinical study was a phase 1 study with the intentions to assess safety, tolerability, 
effects on lipids and pharmacokinetics of repeated oral doses of the PPARA agonist 
AZD4619. The study included 20 healthy males randomized to receive once-daily 
doses of 5 mg AZD4619 (n=15) or placebo (n=5) for 21 days. The ages of the 
participants were ranged from 20-29 years and their BMI were between 20 to 27. 
 
3.1.16 Statistical Analysis (paper I-IV) 
In order to establish differences in reporter vector activity or miRNA/mRNA 
expression between control and treated cells, Student's t-tests (two-tailed) were used 
(papers I-IV). For differences in the variables measured over time in the clinical data in 
paper II, the paired t-test was used. Significant differences are indicated as: *p<0.05, 
**p<0.01, ***p<0.001.  
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4 RESULTS AND DISCUSSION 
 
4.1 PPARD activation increases expression of the human apolipoprotein gene 
(paper I) 
 
ApoA-II is one of the major apolipoproteins of the HDL particle but its anti-
atherogenic role is not as established as for apoA-I [10]. However, recent data show 
that apoA-II is associated with a decreased risk of CVD [182]. The PPARA activating 
fibrates are shown to increase the levels of both apoA-I and apoA-II in plasma in 
humans, as well as the HDL cholesterol, supporting the role of apoA-II as anti-
atherogenic. Moreover, obese rhesus monkeys treated with the PPARD agonist 
GW501516 show elevated plasma levels of apoA-I and apoA-II, as well as increased 
HDL cholesterol levels, further suggesting a beneficial role of apoA-II [95]. It is 
established that the effect of the fibrates on the apoA-II gene is mediated through a 
PPRE in the proximal promoter located at -737/-717, denoted the J-site [84]. In 
contrast, there is no information about the effects of PPARD activation on the apoA-II 
gene, hence we decided to investigate this matter. Treatment of HepG2 cells with the 
PPARD agonist GW501516 increased expression of apoA-II mRNA by 1.22-fold as 
measured by quantitative real-time PCR. Transient transfections of a 3 kb promoter 
construct of apoA-II in both HepG2 and HuH-7 cells showed that the effect was due to 
increased transcription and that a cotransfected PPARD plasmid potentiated this effect. 
The apoA-II promoter was analysed in silico to identify putative PPREs and, additional 
to the J-site, one putative PPRE was found at -2656/-2636, denoted the O-site. This site 
contained an equal number of identical nucleotides of the core PPRE consensus as the 
J-site. Furthermore, the O-site contained 4/7 matches in the 5'-flanking region 
compared to only 2/7 in the J-site (Fig. 11). Interestingly, sequential mutagenesis of 
these two PPREs in the promoter revealed that the effect of the PPARD agonist was 
mediated only through the J-site and not the O-site.  
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As previously reported [84] not only PPAR-induced activity was abolished when the J-
site was mutated but also the basal activity decreased, reflecting the fact that the J-site 
is an important regulatory region also for other members of the nuclear receptor 
superfamily [183]. Both electromobility shift assays (EMSA) and chromatin 
immunoprecipitation assays (ChIP) confirmed the binding of PPARD to the J-site, 
establishing the role of apoA-II as a PPARD target gene. Increased transcription of the 
apoA-II gene is relevant for the abundance of apoA-II in plasma, since the apoA-II 
levels are controlled mainly by its synthesis rather than catabolism [184]. Whether the 
effects of an increase in apoA-II levels after PPAR agonist treatment adds on to the 
effects of the concurrent increase in apoA-I remains to be elucidated. The average 
apoA-I/apoA-II molecular ratio in human plasma is 2:1, which suggest that such an 
abundant protein should have important physiological functions [185]. Since increased 
synthesis of apoA-II is correlated with elevated plasma HDL concentrations, apoA-II 
might be one of many genes responsible for the beneficial effects regarding lipid and 
lipoprotein metabolism observed as a result of PPARD activation. 
 
4.2 PPAR agonists regulate the ALT1 gene expression in human hepatocytes 
(paper II) 
Even though ALT activity is used as a standard marker for hepatotoxicity in human 
clinical trials of pharmaceutical drugs, not much is known about the regulation of the 
two ALT genes, GPT1 and GPT2. The genes give rise to ALT1 and ALT2, 
respectively, which have similar enzymatic activities. ALT1 is highly expressed in 
liver, skeletal muscle and kidney, whereas ALT2 is found in skeletal muscle and heart 
but not in the liver and kidney [44]. Hence, ALT1 is the dominant isoform expressed in 
Figure 11. Comparison of the putative PPREs in the apoA-II promoter 
Comparison of identified PPREs in the apoA-II promoter designated as the O-site and J-site, 
respectively, and the consensus PPRE sequence. The number of matches for the 5'- flanking region 
and the core DR1, respectively, compared to the consensus sequence are shown to the right. 
Identical nucleotides between the consensus sequence and the PPRE are denoted by an asterisk. 
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the liver and it has been shown to be responsible for the basal ALT activity of human 
normal serum [44]. In a phase I clinical trial of AZD4619, a new PPARA activating 
compound developed by Astra Zeneca, the serum ALT levels increased over time in 
some of the participants. The trial went on for 21 days and at the last day of dose, five 
of the 15 participants had ALT levels above upper level of normal (ULN), defined as 
the 95 percentile of ALT activities from pre-dose (Fig. 12). At follow-up at day 31, 
seven of the participants were above ULN. Similarly, AST-levels increased in some of 
the participants during the study but no other liver markers, such as γ-glutamyl 
transferase, t- bilirubin, alkaline phosphatase, pro-thrombin or creatine kinase, were 
elevated. However, due to the increased ALT and AST levels, AZD4619 was 
discontinued from development.  
 
 
 
 
Since previous in vitro studies have shown that the AST gene is transcriptionally 
regulated by PPARA [186] we focused on testing the hypothesis that PPAR agonists 
regulate ALT gene expression. The PPARA agonist fenofibric acid was used as a 
model compound for PPARA activation and increased ALT1 expression in human 
primary hepatocytes compared to untreated cells, as measured by Western blot. 
Fenofibric acid treatment also increased mRNA expresson of ALT1 in three out of five 
different donors of primary hepatocytes measured by quantitative real-time PCR, 
indicating that the effect varies between individuals. Treatment of the hepatoma cell 
Figure 12. Serum ALT activities in healthy volunteers treated with AZD4619 
15 human subjects were treated daily with 5 mg AZD4619 for 21 days. Serum ALT 
activities (U/l) increased after treatment with AZD4619 in some of the 15 subjects. 
ULN = upper level of normal 
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line HuH-7 with fenofibric acid showed that ALT1 but not ALT2 mRNA expression 
was induced after the treatment compared to untreated cells. To establish if the effect 
was transcriptional, two kb of the GPT1 and GPT2 promoters, respectively, were 
cloned into a reporter vector and subsequently used in transient transfection assays in 
HuH-7 cells. Both fenofibric acid and AZD4619 showed dose-dependent increases of 
ALT1 promoter activity, whereas the ALT2 promoter did not respond. Thus, the effects 
of PPARA on ALT enzyme activity are accounted for by ALT1. Furthermore, PPARG 
and PPARD agonists were also shown to activate the ALT1 promoter, indicating that 
all the PPARs had similar effect on the promoter. In contrast, other potent compounds 
such as 12-O-Tetradecanoylphorbol 13-acetate (TPA) and TNFα did not activate the 
ALT promoter (Fig 13).  
 
 
 
 
 
 
Using in silico tools, the promoter of GPT1 was screened for PPREs and seven putative 
sites were found. EMSA studies verified that PPARG could bind to a site located at 
-574 in the promoter, whereas it could not bind to the other putative PPREs. 
Furthermore, mutation of the -574 site abolished the binding of PPARG in the EMSA 
and reduced the responsiveness to PPAR agonists of the promoter construct. 
Noticeably, PPARA did not bind to this site using EMSA, even though it could bind to 
the control rat ACO-PPRE. Importantly, PPARG is known to bind more strongly than 
the other PPARs to PPREs and the lack of binding of PPARA in this study might be 
due to suboptimal conditions of the EMSA or to the fact that the PPRE was weak [76]. 
Figure 13. Induction of ALT1 promoter by PPAR agonists in transfection assays  
PPARA agonists: Fenofibric acid (FA), Clofibrate (clofib.); PPARG agonist: Rosiglitazone (Rg); 
PPARD agonist: GW501516; Miscellaneous: 12-O-Tetradecanoylphorbol 13-acetate (TPA), 
tumour necrosis factor alpha (TNF-α). 
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Since EMSA only reflects binding to naked DNA, a ChIP was performed to evaluate 
the effects of the PPAR agonists in the presence of chromatin. The ChIP confirmed 
binding of both PPARA and PPARG to the -574 PPRE. This study shows that PPAR 
agonists can induce ALT1 by increased transcription of the ALT1 gene which is an 
alternative explanation for increased ALT protein in plasma. 
 
Since ALT was introduced in clinical monitoring during the 1950s [43], much attention 
has been given to its role as a hepatotoxicity marker. In contrast, the function of ALT as 
a metabolic enzyme important for gluconeogenesis has not been given much notice. It 
is known that plasma ALT and AST levels increase in people experiencing a rapid 
weight loss, peaking after 2 weeks [187]. The extreme gluconeogenic condition is a 
possible explanation for the induction of the aminotransferases in the liver during 
fasting [188, 189]. Elevations in aminotransferase levels are also associated with 
obesity and the metabolic syndrome [190, 191], even though it is unknown whether it is 
the obesity per se which affect ALT activity or not. Furthermore, increased plasma 
ALT levels are shown to predict the incidence of type-2 diabetes and cardiovascular 
disease [191, 192]. Gluconeogenesis is increased in subjects with type-2 diabetes and 
the elevated ALT levels might be due to a an enzyme induction as the need for 
aminotransferases in the liver increases [193]. Thus, ALT elevations in plasma might 
not only reflect a hepatic injury but the metabolic status of the liver might also play a 
role for plasma ALT levels. In further support of this alternative hypothesis for ALT 
elevations is the fact that PPARA is important for gluconeogenesis. PPARA knock-out 
mice show impaired gluconeogenesis as a response to fasting compared to PPARA 
wild-type mice [82]. Hence, it is likely that activation of PPARA agonists would induce 
ALT expression in the liver. Furthermore, moderate but transient elevations in ALT 
and AST levels are seen in approximately 10 % of the patients treated with fenofibric 
acid without any other signs of liver injury [50, 51]. This individual variation was also 
observed in our study where only some individuals responding to AZD4619 treatment 
with increased aminotransferase levels. Also, there was a difference in the response in 
ALT expression after treatment with fenofibric acid between the different hepatocyte 
donors. The PPARG agonists have never been associated with transaminase elevations 
in the clinic, unless they have been proven to be toxic, as in the case with Troglitazone. 
Instead PPARG agonists are shown to reduce ALT activity in serum [194], probably 
due to the fact that they improve the insulin sensitivity, which reduces gluconeogenesis 
in the liver [195]. The alternative hypothesis of ALT induction by drugs influencing 
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metabolism was recently demonstrated to be valid also in vivo [196]. Rats treated with 
dexamethasone for 24 hours showed increased levels of ALT activity in the serum and 
in the livers compared to untreated rats, without any signs of tissue damage within this 
time. The dexamethasone treated rats also showed increased amounts of glycogen in 
their livers, indicating an increased gluconeogenesis, which reflects the condition 
induced by the treatment.  
 
Of note, the moderate and transient increase in ALT activity induced by the PPAR 
agonists should be distinguished from the massive increases that occur during liver 
damage. The development of additional hepatotoxicity markers would be important for 
use in combination with ALT so that the new PPAR compounds have a chance to pass 
the clinical monitoring of today.  
 
4.3 Regulation of PPARD by alternative splicing (paper III) 
Since the majority of studies on PPARD concern the effects of its activation, we 
decided to investigate its regulation and more specifically; whether it is subjected to 
alternative splicing, which might give rise to additional isoforms and/or influence the 
expression. The human PPARD gene consists of 9 exons of which exons 1-3, the 5'-end 
of exon 4 and the 3'-end of exon 9 are untranslated [92]. In this study, five new 
alternative exons were identified in the PPARD gene by 5'-RACE using cDNAs from 
placenta, adipose tissue and pancreas and these exons make up a variable range of 
PPARD mRNA species (Fig.14 ). TaqMan analysis using a panel of human cell lines 
and tissues revealed that the most common splice variant encompassed exon 2 
connected to exon 4 (Fig 14, B), whereas the other splice variants were expressed at 
much lower levels.  In vitro transcription/translation and Western blot analysis showed 
that the various transcripts were translated into PPARD protein with different 
efficiencies, inversely correlated to the length, as well as the number of AUGs in the 5'-
UTR. Analysis of basal activity of the previously identified promoter upstream of exon 
1 and the alternative promoters upstream of the newly identified putative transcription 
start sites (Fig 14, H-K) in transient transfection assays, revealed that the promoter 
upstream of exon 1 is the major region for transcriptional activation.  
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Figure 14. A schematic representation of the PPARD gene  
Coding exons (white boxes), previously reported untranslated exons or part of exons (grey boxes), and 
herein identified untranslated exons (black boxes). The variety of splicing among untranslated exons 
and alternative 5'-ends identified by 5' RACE is shown below the gene (5'-UTRs: A-K). 
 
Moreover, a 3' splice transcript encoding a truncated isoform of PPARD, PPARD2, 
was identified in placenta and adipose tissue. This truncated variant is formed due to 
intron retention of intron 8 which introduces an early stop codon, leading to a truncated 
PPARD protein lacking 82 amino acids of the C-terminal containing the ligand-binding 
domain. Analysis of PPARD2 in transient transfection assays revealed that it could not 
be transactivated by ligand-binding but rather repressed ligand-induced activation of 
PPARD1, constituting a dominant negative inhibitor of the full-length receptor. 
Furthermore, PPARD2 was unable to bind to a classical PPRE in EMSA studies, 
suggesting that it does not compete with PPARD1 for DNA-binding as is suggested for 
the dominant negative full-length mouse orthologous of PPARD (E411P) [197, 198]. 
The mechanism of inhibition of PPARD2 might instead be due to competition for 
cofactors or its heterodimerization partner RXR, which has been speculated as the 
negative regulatory mechanism for some of the other truncated nuclear receptors [132, 
133, 135, 136]. 
 
The diversity in PPARD 5'- transcripts described in this study adds another level of 
regulation. Post-transcriptional regulation by 5'-splicing have already been described 
for the mouse PPARD [199] and also for the human PPARA and PPARG genes [200, 
201] where the PPARG transcripts also have shown to influence translational efficiency 
[202]. The mechanism which accounts for differences in translational efficiency 
between the 5'-splice variants of PPARD is not clear but the fact that long 5'-UTRs and 
number of AUGs play a role indicate that secondary structures of the 5'-UTR or 
upstream open reading frames (uORF) might be involved [203]. A study regarding 
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alternative 5'-transcripts of PPARG identified that the stability of the 5'-UTRs is 
inversely related to the translational efficiency [202]. Even though alternative 
promoters have been described to be functional in the mouse PPARD gene [199], the 
promoter analysis in this study showed low activity compared to the one already 
described. However, it is possible that the promoters described here might be functional 
in tissues other than the ones tested in this study, due to differential expression of 
cofactors. Truncated isoforms have been described for the other members of the PPAR 
family and for many of the other nuclear receptors. The mechanism of inhibition of 
PPARD2 remains to be elucidated but general mechanisms suggested for the other 
nuclear receptors are; competition for binding to the DNA, competition for 
cofactors/auxiliary factors or for heterodimerization partners, or influences on nuclear 
localisation [132-136]. The conclusion of this study is that alternative splicing of 
human PPARD could constitute an intrinsic role for the regulation of PPARD 
expression and activity, which could be of relevance both in physiology and disease.  
 
4.4 Regulation of PPARD by miRNA (paper IV) 
In order to further investigate the mechanisms governing the regulation of the human 
PPARD gene, the 3'-UTR of PPARD was analysed in silico for miRNA binding sites 
using the UCSC genome browser. Two putative miRNA target sites were identified, 
miR-9 and miR-29 (Fig 15).  
 
   
 
 
 
Transient transfection assays in HEK293 cells using a PPARD 3'-UTR reporter 
construct showed decreased luciferase expression when miR-9 was cotransfected, 
whereas miR-29 or the control miR-155 did not alter the luciferase activity,  indicating 
that miR-9 can regulate the PPARD gene. Furthermore, when the miR-9 target site was 
mutated, the effect of miR-9 was abolished, demonstrating that the regulation of the 3'-
UTR by miR-9 was mediated through the in silico identified miR-9 site (Fig 16). 
Figure 15.  Schematic representation of the PPARD 3'-UTR luciferase reporter construct  
Putative target sites for miRNAs and their corresponding miRNA sequences are shown below. 
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Moreover, a luciferase reporter containing only the short sequence coding for the miR-
9 target site (36 bp) also showed decreased luciferase activity after coexpression of 
miR-9, whereas mutation of the seed sequence abolished the luciferase activity. Also, 
cotransfection of an antisense of miR-9, antagomiR-9, in the absence of any 
cotransfected miR-9, showed an increase in luciferase activity in cells transfected with 
the PPARD 3'-UTR or the short miR-9 construct. Furthermore, when miR-9 was 
transfected into the cells, the luciferase activity could be restored to almost normal 
levels by antagomiR-9. These results strongly support the finding that miR-9 represses 
PPARD protein expression. In contrast, miR-29 did not affect the expression of the 
full-length 3'-UTR PPARD reporter, indicating that it is not a regulator of PPARD. To 
elucidate whether miR-9 targets only the PPARD protein levels or if mRNA levels also 
are affected, miR-9, miR-29 or the empty plasmid was transfected into HEK293 cells 
for 24 h and PPARD mRNA expression was measured by quantitative real-time PCR. 
However, no difference between the groups could be detected which suggests that miR-
9 does not affect the levels of the PPARD transcript, instead it inhibits the translation of 
the mRNA into protein.  
 
Since miR-9 has been shown to play an important role in the inflammatory response in 
monocytes [204], the relevance of miR-9 regulation in relation to PPARD expression 
was investigated in monocytes and macrophages. Based on the knowledge that 
treatment of primary monocytes with LPS increases miR-9 expression [204], human 
primary monocytes were treated with LPS to study the effects on PPARD function. 
Accordingly miR-9 expression as well as PPARD mRNA expression was increased 
Figure 16.  The PPARD gene is a direct target of miR-9  
Luciferase activity of reporter constructs that contain the wild-type (grey bars) of the 
entire PPARD 3'-UTR or mutated at the putative miR-9 binding site (black bars). 
HEK293 cells were transiently cotransfected with the PPARD 3'-UTR reporter 
constructs and expression vectors coding for miR-155, miR-9 or miR-29 as indicated. 
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after both 8 and 24 hours treatment. However, the PPARD target genes adipose 
differentiation-related protein (ADFP), adipose triglyceride lipase (ATGL) and 
carnitine palmitoyltransferase (CPT1) were notably lower after 8 hours treatment and 
only increased after 24 hours, suggesting that the increased expression of miR-9 in the 
cells was counter-acting the effects of the PPARD elevation. Western blot analysis of 
monocytes treated with LPS for 24 hours did not show any major differences after LPS 
treatment compared with cells only treated with vehicle, further proposing that PPARD 
protein levels were not as increased by the LPS treatment as the PPARD mRNA 
expression.   
  
Due to the recent identification of PPARD as a major regulator of the M2 phenotype of 
macrophages, the involvement of miR-9 in the alternative activation of macrophages 
was elucidated. Human primary monocytes were differentiated into macrophages and 
subsequently treated with LPS and IFNγ to become M1 macrophages, IL-4 to become 
M2 macrophages or vehicle to serve as control (M0) for 6, 24 or 72 h. Of note, PPARD 
mRNA expression was higher in M1 compared to M2 macrophages at 24 and 72 hours, 
whereas mRNA expression of PPARG was higher in M2 compared to M1 at all time 
points measured. Analysis of miR-9 expression revealed no statistical difference 
between the treatments suggesting that miR-9 expression is not involved in the 
development of different macrophage phenotypes. 
 
MiR-9 is a microRNA which has been reported to be involved in distinct processes 
such as neuronal differentiation in the brain, release of insulin from the pancreas and 
the immune response in monocytes [204-206]. By increasing concomitantly with NFκB 
in monocytes and targeting its 3'-UTR, miR-9 inhibits the inflammatory cascade and 
constitutes a negative feed-back loop of the inflammatory response [204]. Similarly, 
this study shows that PPARD gene expression is increased in monocytes during 
inflammatory stimulation with LPS and the protein expression is partly inhibited by the 
simultaneous increase in miR-9. The importance of PPARD for the inflammatory status 
of macrophages is not clear but recent studies in murine macrophages suggest a 
function of PPARD in inflammation, by causing a switch from M1 to M2 phenotype 
[29, 30]. However, in this study PPARD expression was higher in M1 than M2 
macrophages, which supports data from a recent human study [31], highlighting the 
differences between human and mouse macrophages. The lack of differences in 
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miRNA expression between the macrophage subtypes suggests that the function of 
miR-9 is of importance only in monocytes but not in differentiated macrophages.  
 
 
 40 
5 GENERAL DISCUSSION 
 
PPARD is a protein with multiple functions in basically all the tissues of the human 
body. When the PPAR family was discovered in the early 1990:ies, PPARD was not 
considered to be more than a house-keeping gene in the shade of PPARA and PPARG, 
the important mediators of the fibrates and glitazones, respectively. Today, when 
detrimental side-effects associated with some of the PPARG agonists have been shown 
and the role of PPARD as a nuclear receptor with beneficial effects on both lipid 
metabolism and insulin sensitivity have become more clear, a number of studies 
regarding its functions have emerged. The increased oxidative capacity in muscle, 
increased fatty acid combustion in adipose tissue and beneficial effects on lipoprotein 
metabolism are clear indicators of overall positive effects mediated by PPARD, which 
could be taken advantage of in the treatment of obesity and type-2 diabetes. However, 
caution has to be taken since PPARD has been reported to increase cell proliferation 
and to be involved in cancer formation in the colon, even though the literature on the 
subject is not totally conclusive [207] . 
 
The first two studies of this thesis further supports the role of PPARD as an important 
regulator of human lipoprotein composition and overall metabolism. The increased 
expression of apoA-II mediated by transactivation of PPARD is likely one of the 
reasons for the increase in the number of HDL particles and the enhanced reverse 
cholesterol transport in primates and humans treated with GW501516. The activation 
of the ALT1 gene in the liver by all three PPARs implies that increases in lipid 
oxidation results in a state of the body that favors gluconeogenesis including the 
enzymes implicated in that process. Hence, PPAR activation mimics a state of 
starvation of the body which could be taken advantage of in obesity and obesity-related 
disorders such as type-2 diabetes and cardiovascular disease. However, if the ALT 
enzymes are to be assessed during clinical trials of developing PPAR agonists, an 
awareness of the properties of the PPARs to induce aminotransferases by the non-toxic 
mechanism is important. 
 
The effects of PPARD have mainly been investigated using activation of the receptor 
by a specific ligand, or by studying the effects of PPARD knock-out or transgenic mice 
models. These studies show the importance of PPARD activation in lipid metabolism 
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but have also identified an inflammatory role of the receptor in macrophages. As 
demonstrated by the LDL receptor knock-out mouse model, a reduction in plaque size 
is seen both after knock-out of myeloid PPARD and after PPARD activation, due to its 
sequestering of inflammatory corepressors in the unliganded state [73]. Hence, the 
effects of regulation of the gene are complex, since not only abundance of the protein 
but also availability of ligands is important for its downstream effects. Additionally, the 
availability of coactivators and corepressors, as well as availability of the other PPAR 
family members or other nuclear receptors might determine the response of PPARD 
expression or activation [71, 72]. Hence, studies of this nuclear receptor have to be 
performed in a well controlled experimental setting. No detailed investigations on the 
regulation of the human PPARD gene has been performed until now, even though the 
mouse gene has been reported to be regulated by alternative promoter usage and 
alternative splicing [199]. In this thesis, human PPARD is shown to be subjected to 
alternative splicing in the 5'-end, which results in differences in translational efficiency 
between the different transcripts. Furthermore, a 3'-truncated PPARD isoform, 
PPARD2, is shown to be a negative regulator of the full length variant. These findings 
could be of importance for PPARD expression in different tissues or during different 
metabolic conditions, however, the functional relevance of the splice variants remains 
to be identified. Furthermore, the mechanism of negative regulation of PPARD2 still 
remains to be elucidated. 
 
Regulation of PPARD by miRNA was also identified as a posttranscriptional regulatory 
mechanism of the human PPARD gene. However, to understand the importance of 
PPARD regulation by miR-9, further studies of PPARD function in monocytes is 
needed. Since miR-9 is highly expressed in the brain and PPARD expression is 
important for myelination of the corpus callosum [100], the brain might be one of the 
main sites of PPARD regulation by miR-9. Additionally, the concomitant increase of 
PPARD and miR-9 in monocytes after inflammatory stimulation suggests a tight 
relationship between these two players during the initial inflammatory response of 
monocytes, and might be relevant in the initiation of the atherosclerotic process.  
 
The future for PPARD as a drug target is not easy to predict. With the declining interest 
for the PPARA and PPARG agonists on the market, a PPARD compound might take 
over as their replacement therapy. However, the aminotransferase elevations of PPARA 
agonists in clinical trials as well as the failures of some of the PPARG agonists which 
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have been on the market for many years, the PPARs in general have a bad reputation. 
Also, non-resolved issues about its involvement in tumour formation are of major 
concern, even though there has been no indication of increased tumourogenesis in the 
millions of patients taking fibrates or glitazones. Another obstacle for the development 
of PPAR agonists is the fact that all new PPAR ligands require two years of preclinical 
oncogenicity studies prior to initiating any clinical studies of 6 months and longer, 
which might not make the effort worth-while for pharmaceutical companies [118]. 
However, tissue-specific PPAR modulators (SPPARMS) might be the resolution to this 
problem. The future might hold a muscle-specific PPARD modulator that will be 
prescribed additionally to exercise to patients with the metabolic syndrome. The 
exercise itself would increase PPARD expression in the skeletal muscle and the drug 
would cause its activation, resulting in increased expression of genes involved in lipid 
oxidation. The increased oxidation of fatty acids in the muscle increases the overall 
insulin sensitivity, and is beneficial for the endurance capacity of the muscle fibers. Of 
note, not the PPARD agonist itself but the combination of exercise and PPARD agonist 
is important for the beneficial effects, as recently demonstrated by a study of sedentary 
mice administrated either with GW501516 alone or in combination with an exercise 
program [208]. Exercise not only increases PPARD expression in skeletal muscle but 
also improves the metabolic status of the patients, which might be relevant for the 
synergic function of PPARD activation and exercise.  An alternative might be to 
influence the splicing machinery to only create short 5'-ends of PPARD mRNA, hence 
increasing the translational efficiency. Whether that is applicable or not is too early to 
say but the idea is intriguing. Treatment with an antagomiR-9 might also be a way to 
increase PPARD expression. However, miR-9 have additional targets, both known and 
unknown which probably would cause numerous side-effects. To be able to modulate 
this receptor in a clinical setting, it is important to further elucidate by which 
mechanisms it is regulated. With increasing knowledge about different functions of 
PPARD, additional studies on the regulation of this nuclear receptor will probably 
emerge to resolve new treatments for metabolic syndrome and CVD. Until then, 
exercise in combination with a high dietary intake of PUFAs will be the most effective 
way to increase the expression of PPARD and subsequently cause its activation, not 
only to treat but also to prevent the development of the metabolic syndrome. 
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6 CONCLUSIONS 
 
The work of this thesis has identified new target genes of PPARD and also revealed 
post-transcriptional mechanisms of regulation of this nuclear receptor. In summary, the 
conclusions of this thesis are; 
 
• Paper I: PPARD activation increases the expression of the human apoA-II gene, 
which might be one of the reasons why treatment with PPARD agonist increases 
production of HDL particles and stimulates reverse cholesterol transport.  
• Paper II: The ALT1 gene is a transcriptional target of the PPARs, which may 
result in mild ALT elevations in plasma in the absence of liver injury when 
assessing new PPAR agonists in clinical trials. 
• Paper III: PPARD is subjected to alternative splicing, both in the 5'- and 3'-ends, 
which identifies possible mechanisms for PPARD regulation in time and space. 
• Paper IV: The human PPARD gene is regulated by miRNA-9, which might be 
important for the early inflammatory response in monocytes. 
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